• Telehealth specialist Global Health signs partnership deal with Woolworths subsidiary
  • The deal will see Global Health provide virtual access to healthcare practitioners
  • Orthocell hires experts to drive US market entry

 

Telehealth specialist Global Health (ASX:GLH) jumped as high as 5% this morning after announcing a partnership with Woolworth Group’s subsidiary, HealthyLife initiative.

The deal will see the implementation of HealthyLife’s new telehealth service which provides virtual access to healthcare practitioners via a network of GPs, dietitians, nutritionists and in-house naturopaths.

The Global Health software will support this initiative by providing a third-party platform that connects customers with these qualified service providers.

The company will provide three SaaS platforms – including Hothealth for online forms, online appointments and telehealth consults, ReferralNet for Securing Messaging, and M+ for Allied Health practitioners.

The rise of the Covid-19 pandemic has led to a significant increase in telehealth consultations, which have also been supported by the Australian Government through programs such as mental health care plans.

“Over the past three years, telehealth has been at the forefront of consumers’ minds all across Australia,” said Mathew Cherian, CEO of Global Health.

“Telehealth has been an easy and safe way for patients to access healthcare providers in times where they aren’t able to access their regular practitioners.

“HealthyLife’s goal of encouraging proactive consumer involvement in conjunction with their healthcare team is strongly aligned to our vision of connecting clinicians and consumers.”

 

Orthocell hires experts to drive US market entry

Medical devices specialist Orthocell (ASX:OCC) has appointed internationally recognised orthopaedic surgeons, Professor Christopher Dy and Professor David Brogan, to its Medical Scientific Advisory Board.

Professors Dy and Brogan are based at Washington University and Barnes-Jewish Orthopedic Center respectively, and were appointed to assist with clinical development and US market access for Orthocell’s nerve repair medical device.

Orthocell believes both surgeons bring a wealth of clinical and research expertise, and will provide Orthocell the know-how to drive its nerve repair medical device into the US market.

“These appointments, along with the recent appointment of Dr Ravi Thadhani to the Orthocell board of directors, adds significant depth to our US team and ability to execute our commercialisation plans,” said Orthocell CEO, Paul Anderson.

 

Share prices today:

 

 

Read MoreBiotech

Featured Companies

You might be interested in